Lonza, the world-leading Swiss contract development and manufacturing organization (CDMO), has chosen Hyderabad as the location for its new Global Capability Center (GCC). The facility will serve as a strategic hub for digital transformation, data analytics, AI/ML applications, process optimisation, and support functions for Lonza’s global biopharma operations further solidifying Hyderabad’s emergence as India’s premier life sciences and advanced manufacturing destination.
Glimpse:
Announced on January 28, 2026, the Hyderabad GCC will initially employ 500–800 highly skilled professionals in data science, bioinformatics, automation, supply chain analytics, and regulatory informatics, with plans to scale to 2,000+ within 3–5 years. Lonza cited Hyderabad’s deep talent pool in life sciences and IT, world-class infrastructure, supportive government policies, and proximity to growing biologics manufacturing clusters as key decision factors. The center will support Lonza’s global network of 20+ production sites and accelerate innovation in cell & gene therapies, mRNA platforms, and next-generation biologics.
Lonza Group AG, the Swiss-based global leader in biologics, cell & gene therapies, and small-molecule CDMO services, has officially selected Hyderabad as the location for its new Global Capability Center (GCC). The announcement, made on January 28, 2026, marks a significant milestone in Lonza’s long-term strategy to build a world-class digital and analytical backbone that supports its global manufacturing footprint and accelerates innovation for biopharma customers.
The Hyderabad GCC will focus on high-value, knowledge-intensive functions including:
- Advanced data analytics and AI/ML for process optimisation and predictive maintenance
- Bioinformatics and computational biology for cell & gene therapy development
- Digital supply chain and manufacturing execution systems
- Regulatory informatics and compliance automation
- Finance, procurement, HR, and IT shared services
Initial hiring will target 500–800 professionals in 2026–2027, with rapid scaling planned to exceed 2,000 employees within 3–5 years. The center will operate as a strategic extension of Lonza’s global R&D and operations network, closely collaborating with sites in Switzerland, the U.S., Singapore, and the Netherlands.
Lonza cited several factors for choosing Hyderabad:
- Deep pool of talent in life sciences, biotechnology, data science, and IT
- World-class infrastructure (HITEC City, Genome Valley proximity, international airport)
- Supportive government policies under Telangana’s Life Sciences Policy and incentives for GCCs
- Growing biologics and vaccine manufacturing ecosystem in the region
- Cost-competitive yet high-quality operating environment
Lonza Executive Committee Member commented: “Hyderabad offers the perfect combination of scientific talent, digital ecosystem, and government support to become a cornerstone of Lonza’s global capability network. This new GCC will play a critical role in driving efficiency, innovation, and digital transformation across our entire CDMO platform.”
The facility is expected to be operational by late 2026, initially in leased space in Hyderabad’s HITEC City or Financial District, with plans for a dedicated campus in subsequent phases. The investment aligns with Telangana’s ambition to become India’s leading life sciences and bioeconomy hub, following major commitments from global players such as Novartis, Pfizer, and Thermo Fisher.
The move is also seen as a vote of confidence in India’s growing role in global biopharma R&D and digital enablement, even as physical manufacturing remains concentrated in the U.S., Europe, and Singapore.
“Hyderabad is no longer just a cost effective location it is a high value innovation hub. Establishing our GCC here allows Lonza to tap into India’s best talent while accelerating digital capabilities that benefit our customers worldwide.”
By
HB Team
Related News
